S3 - ALS: Disease Mechanism and Therapeutics

Event Time: Sunday April 23, 2017 1:00 pm to 3:00 pm
Topic(s): Neuromuscular and Clinical Neurophysiology (EMG)
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:24 PM 003 Postnatal CRISPR-mediated genome editing prolongs survival in a mouse model of amyotrophic lateral sclerosis Zachary Kennedy
Dr. Kennedy has nothing to disclose.

1:36 PM 004 Plasma Neurofilament Heavy Chain Levels correlate with disease severity and progression on multiple clinical outcomes in Amyotrophic Lateral Sclerosis (ALS) Steve Han, MD PhD
Dr. Han has received personal compensation for activities with Biogen Idec as an employee. Dr. Han holds stock and/or stock options in Biogen Idec.

1:48 PM 005 Distinct patterns of disease progression in SOD1-associated familial ALS: A study of 25 mutations. Pooled analysis of two trials of pyrimethamine in familial ALS. Pantelis P. Pavlakis, MD
Dr. Pavlakis has nothing to disclose.

2:00 PM 006 Immuno-modulation in Amyotrophic Lateral Sclerosis- A Phase II Study of Safety and Activity of Low Dose Interleukin-2 (IMODALS study) Gilbert Bensimon, MD
Dr. Bensimon has nothing to disclose.

2:12 PM 007 The NEALS Randomized, Placebo Controlled Trial of Diaphragm Pacing in Patients with ALS Jonathan Katz, MD
Dr. Katz has nothing to disclose.

2:24 PM 008 The polymorphisms of CX3CR1 gene influence ALS survival in an Italian population-based study Cristina Moglia
Dr. Moglia has nothing to disclose.

Register Now

Related Courses